ArticleFrontiers in neuroscience2011
Metabotropic glutamate receptors as novel therapeutic targets on visceral sensory pathways.
Article in Frontiers in neuroscience, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 37 citations in OpenAlex.
- Trial
- Interplay Among Synaptic Glutamate Release and Excitotoxicity: Neuronal Damage and Graphene-Based Materials Related Protection.Life (Basel, Switzerland) · 2025Review
- Inhibition mediated by group III metabotropic glutamate receptors regulates habenula activity and defensive behaviors.Nature communications · 2025Article
- Article
- Review
- Epithelial-Neuronal Communication in the Colon: Implications for Visceral Pain.Trends in neurosciences · 2020Review
- AMPA receptor-mTORC1 signaling activation is required for neuroplastic effects of LY341495 in rat hippocampal neurons.Scientific reports · 2020Article
- Ischemia-Triggered Glutamate Excitotoxicity From the Perspective of Glial Cells.Frontiers in cellular neuroscience · 2020Article
- In vivo evidence for dysregulation of mGluR5 as a biomarker of suicidal ideation.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- Glutamate-Modulating Drugs as a Potential Therapeutic Strategy in Obsessive-Compulsive Disorder.Current neuropharmacology · 2017Review
- Article
- Vagal neurocircuitry and its influence on gastric motility.Nature reviews. Gastroenterology & hepatology · 2016Review
- Pharmacological attenuation of chronic alcoholic pancreatitis induced hypersensitivity in rats.World journal of gastroenterology · 2015Article
- Negative allosteric modulation of the mGlu7 receptor reduces visceral hypersensitivity in a stress-sensitive rat strain.Neurobiology of stress · 2015Article
- Tweeters, Woofers and Horns: The Complex Orchestration of Calcium Currents in T Lymphocytes.Frontiers in immunology · 2015Review
- Stress-induced visceral pain: toward animal models of irritable-bowel syndrome and associated comorbidities.Frontiers in psychiatry · 2015Review
- Role of metabotropic glutamate receptors in the regulation of pancreatic functions.Biochemical pharmacology · 2014Review
- Female reproductive tract pain: targets, challenges, and outcomes.Frontiers in pharmacology · 2014Review
- The gut as a sensory organ.Nature reviews. Gastroenterology & hepatology · 2013Article
- VGLUTs in Peripheral Neurons and the Spinal Cord: Time for a Review.ISRN neurology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabotropic glutamate receptors (mGluR) have a diverse range of structures and molecular coupling mechanisms. There are eight mGluR subtypes divided into three major groups. Group I (mGluR1 and 5) is excitatory; groups II (mGluR2 and 3) and III (mGluR 4, 6, and 7) are inhibitory. All mGluR are found in the mammalian nervous system but some are absent from sensory neurons. The focus here is on mGluR in sensory pathways from the viscera, where they have been explored as therapeutic targets. Group I mGluR are activated by endogenous glutamate or constitutively active without agonist. Constitutive activity can be exploited by inverse agonists to reduce neuronal excitability without synaptic input. This is promising for reducing activation of nociceptive afferents and pain using mGluR5 negative allosteric modulators. Many inhibitory mGluR are also expressed in visceral afferents, many of which markedly reduce excitability. Their role in visceral pain remains to be determined, but they have shown promise in inhibition of the triggering of gastro-esophageal reflux, via an action on mechanosensory gastric afferents. The extent of reflux inhibition is limited, however, and may not reach a clinically useful level. On the other hand, negative modulation of mGluR5 has very potent actions on reflux inhibition, which has produced the most likely candidates so far as therapeutic drugs. These act probably outside the central nervous system, and may therefore provide a generous therapeutic window. There are many unanswered questions about mGluR along visceral afferent pathways, the answers to which may reveal many more therapeutic candidates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.